Astrazeneca plc is paying up to $630 million to acquire China rights to Abelzeta's Pharma Inc.’s C-CAR031 (AZD5851), an autologous glypican 3-targeting CAR T, securing global rights to develop, manufacture and commercialize the CAR T for liver cancer. Read More
China’s National Medical Products Administration has accepted for review Grand Pharmaceutical Group Ltd./Telix Pharmaceuticals Ltd.’s NDA for TLX-591-CDx (Illuccix, gallium Ga 68 PSMA-11), a radionuclide-drug conjugate for diagnosing prostate cancer. Read More
Immunofoco Biotechnology Co. Ltd. reported encouraging early clinical data for its CLDN18.2-targeted CAR T therapy, IMC-002, in heavily pretreated gastric and gastroesophageal junction cancer, adding momentum to the push to extend cellular immunotherapy into solid tumors. Read More
After only three $1 billion-plus biopharma deals in November, December saw 14 blockbuster deals worth a total of $21.92 billion, including four deals worth more than $2 billion. Read More
As China emerges as a critical commercial market and a source of global innovation, the newly released 2026 edition of Clarivate’s Drugs to Watch report highlights six drugs to watch in the China market for the year ahead. Read More
The sea anemone Stichodactyla helianthus, which carpets the Caribbean seafloor, may hold the key to eliminating the senescent cells that survive cancer therapy. A collaboration led by Spanish scientists across several international research centers has discovered a new type of toxin that selectively eliminates senescent cancer cells. Read More
Biopharma financing values have shown quarterly volatility over the past decade, with surges often concentrated in specific quarters rather than evenly distributed throughout the year. Read More
Clinical updates from Asia, including trial initiations, enrollment status and data readouts and publications: Amplia Therapeutics, Immunofoco Biotechnology, Lynk Pharmaceuticals, Teva Pharmaceutical Industries. Read More
Regulatory snapshots, including drug submissions and approvals, clinical trial approvals and other regulatory decisions and designations in Asia-Pacific: Immunitybio, Saofi. Read More
